Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research

Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research
Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Published Jul 13, 2016
59 pages — Published Jul 13, 2016
Price US$ 1,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016, provides an overview of the Ligand Pharmaceuticals, Inc.s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ligand Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Ligand Pharmaceuticals, Inc.
- The report provides overview of Ligand Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ligand Pharmaceuticals, Inc.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ligand Pharmaceuticals, Inc.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Ligand Pharmaceuticals, Inc.s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ligand Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ligand Pharmaceuticals, Inc.s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and sco

  
Source:
Document ID
GMDHC08088CDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Ligand Pharmaceuticals, Inc. Snapshot61
  Ligand Pharmaceuticals, Inc. Overview61
  Key Information61
  Key Facts61
Ligand Pharmaceuticals, Inc. Research and Development Overview73
  Key Therapeutic Areas73
Ligand Pharmaceuticals, Inc. Pipeline Review109
  Pipeline Products by Stage of Development101
  Pipeline Products Monotherapy111
  Pipeline Products Partnered Products121
    Partnered Products/Combination Treatment Modalities133
  Pipeline Products Out-Licensed Products161
    Out-Licensed Products/Combination Treatment Modalities172
Ligand Pharmaceuticals, Inc. Pipeline Products Glance195
  Ligand Pharmaceuticals, Inc. Late Stage Pipeline Products191
    Pre-Registration Products/Combination Treatment Modalities191
    Phase III Products/Combination Treatment Modalities201
  Ligand Pharmaceuticals, Inc. Clinical Stage Pipeline Products211
    Phase II Products/Combination Treatment Modalities211
    Phase I Products/Combination Treatment Modalities221
  Ligand Pharmaceuticals, Inc. Early Stage Pipeline Products231
    Preclinical Products/Combination Treatment Modalities231
Ligand Pharmaceuticals, Inc. Drug Profiles2416
  lasofoxifene tartrate241
    Product Description241
    Mechanism of Action241
    R&D Progress242
  clopidogrel bisulfate261
    Product Description261
    Mechanism of Action261
    R&D Progress262
  aplindore fumarate281
    Product Description281
    Mechanism of Action281
    R&D Progress281
  pradefovir mesylate291
    Product Description291
    Mechanism of Action291
    R&D Progress291
  MB-07133301
    Product Description301
    Mechanism of Action301
    R&D Progress301
  LGD-6972311
    Product Description311
    Mechanism of Action311
    R&D Progress311
  Drug to Inhibit JAK3 for Inflammation321
    Product Description321
    Mechanism of Action321
    R&D Progress321
  LG-7455331
    Product Description331
    Mechanism of Action331
    R&D Progress331
  LGD-3437341
    Product Description341
    Mechanism of Action341
    R&D Progress341
  LGD-7501351
    Product Description351
    Mechanism of Action351
    R&D Progress351
  PS-031291361
    Product Description361
    Mechanism of Action361
    R&D Progress361
  Small Molecule to Antagonize CCR1 for Oncology371
    Product Description371
    Mechanism of Action371
    R&D Progress371
  Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  Small Molecules to Activate Glucokinase for Type 2 Diabetes391
    Product Description391
    Mechanism of Action391
    R&D Progress391
Ligand Pharmaceuticals, Inc. Pipeline Analysis406
  Ligand Pharmaceuticals, Inc. Pipeline Products by Target402
  Ligand Pharmaceuticals, Inc. Pipeline Products by Route of Administration421
  Ligand Pharmaceuticals, Inc. Pipeline Products by Molecule Type431
  Ligand Pharmaceuticals, Inc. Pipeline Products by Mechanism of Action442
Ligand Pharmaceuticals, Inc. Recent Pipeline Updates465
Ligand Pharmaceuticals, Inc. Dormant Projects511
Ligand Pharmaceuticals, Inc. Discontinued Pipeline Products523
  Discontinued Pipeline Product Profiles521
    adipiplon521
    clopidogrel bisulfate521
    LGD-5552521
    managlinat dialanetil521
    NGD-2000-1531
    NGD-91-1531
    NGD-91-2531
    NGD-91-3531
    NGD-94-1531
    NGD-94-4531
    NGD-96-1531
    NGD-97-1531
    Vanilloid Receptor-1 Program541
Ligand Pharmaceuticals, Inc. Company Statement551
Ligand Pharmaceuticals, Inc. Locations And Subsidiaries562
  Head Office561
  Other Locations &Subsidiaries562
Appendix582
  Methodology581
  Coverage581
  Secondary Research581
  Primary Research581
  Expert Panel Validation581
  Contact Us581
  Disclaimer591

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Ligand-Pharmaceuticals-Inc-Product-Pipeline-Review-2016-2088-16186>
  
APA:
Global Markets Direct - Market Research. (2016). Ligand Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Ligand-Pharmaceuticals-Inc-Product-Pipeline-Review-2016-2088-16186>
  
US$ 1,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.